This Obesity Drug Stock Surges 60% on Phase 3 News
A notable fund sold millions of dollars’ worth of shares as this obesity drug stock jumped on Phase 3 momentum. Here’...
Learn how to choose a low-fee Dividend Aristocrats ETF and what fees to watch. This intro covers cost factors and quick tips for a cost-efficient selection.
24,603 articlesA notable fund sold millions of dollars’ worth of shares as this obesity drug stock jumped on Phase 3 momentum. Here’...
Ethereum faces renewed selling pressure after a failed attempt to reclaim key resistance. As the week unfolds, trader...
Janet Jackson headlines a one-off UK show at Sandringham in 2026. This guide breaks down how to budget for tickets, t...
A House of Lords committee urges a redesign of stablecoin safeguards as the UK finalizes rules for pound-denominated ...
Last month, poet technologies skyrocketed 72.6%, delivering a dramatic rally in a volatile sector. This article expla...
Bitcoin hovers near the $62,000 mark as geopolitical tensions flare and inflation prints ignite bets on rates. The cr...
The latest monthly gauge shows a sharper-than-expected slowdown in manufacturing, fueling investor caution as the pat...
SpaceX has pulled back from its recent peak, dropping around 18%. This article explains why this move isn’t a reason ...
Pi2Day brings three new services to Pi Network, expanding into AI, identity, and third-party apps. Markets respond wi...
Palantir’s stock has moved little over the past year despite strong revenue growth, reigniting a debate about michael...
When a biotech firm nears a major FDA decision, every insider transaction can feel like a tell. This article dives in...
A top financial executive recently disclosed a share sale at Robinhood. This article breaks down what the move means,...